D. E. Kainov

The paper develops scoring systems to predict novel broad-spectrum antivirals and combinations, aiming to improve preparedness for future viral outbreaks.

This study examines how active components of commonly prescribed medicines affect influenza A virus-host cell interactions both in silico and in vitro.

This study combines nafamostat and interferon-alpha to suppress SARS-CoV-2 infection by targeting TMPRSS2 in vitro and in vivo.

This study shows that IFNa-based combinations effectively inhibit SARS-CoV-2 infection in vitro and in vivo, with synergistic effects against other viruses.

This study identifies novel synergistic antiviral drug combinations effective against SARS-CoV-2, echovirus 1, HCV, and HIV-1 in vitro and provides an online resource for their developmental status.

This study uses PepSeq to map SARS-CoV-2 antibody epitopes and identifies cross-reactivity with hCoV-OC43.

The paper identifies potent convalescent sera and broad-spectrum antivirals effective against SARS-CoV-2 using a neutralization assay and cell culture screening.

This study shows that Bcl-xL-specific inhibitors, when combined with DNA-damaging agents or physical insults, trigger apoptosis in various cell types and C. elegans by releasing Bad and Bax from Bcl-xL.